PTAB challenges

As a senior PTAB practitioner, I have analyzed the America Invents Act (AIA) trial history for U.S. Patent No. 8,307,116.

Proceedings Overview

A comprehensive search of the USPTO's Patent Trial and Appeal Board (PTAB) dockets confirms that no inter partes reviews (IPRs), post-grant reviews (PGRs), or covered business method (CBM) reviews have ever been filed against U.S. Patent No. 8,307,116. Consequently, all original claims remain unaltered by PTAB proceedings, and the patent has not yet been tested in this specific forum. For a defendant, this means the patent's validity is a clean slate from a PTAB perspective, presenting both an opportunity and a lack of established prior art challenges.

---

Strategic Summary

• Claim Status: All claims of U.S. Patent 8,307,116, including independent claims 1, 8, and 14, are currently valid and enforceable. No claims have been CANCELED, and none have been found patentable over prior art in a Final Written Decision (FWD). All claims are UNTESTED before the PTAB.

• Estoppel Landscape: As there have been no prior IPRs, the estoppel provisions of 35 U.S.C. § 315(e) do not apply to any potential petitioner. A defendant facing an infringement suit, such as Intel in the Western District of Texas, is free to challenge the validity of any and all claims in a new IPR petition based on any patents or printed publications they can identify. The entire universe of prior art is available for a first challenge.

• Pattern Signals: The absence of PTAB proceedings is significant. It suggests that prior to the recent litigation filed in April 2026, this patent was not actively asserted against parties who would typically respond with an IPR. For a patent issued in 2012, this lack of a challenge history is notable and could imply that the current litigation campaign by Empire Technology Development LLC is a recent development. The patent has not been "hardened" by surviving PTAB scrutiny, making it a potentially attractive target for an invalidity challenge.

---

Recommended Next Steps

For a defendant, such as Intel Corporation or any other entity accused of infringing U.S. Patent 8,307,116, the path is clear:

1. Acknowledge the Clean Slate: First and foremost, recognize that no PTAB proceedings are on file. This means there are no prior PTAB arguments, claim constructions, or FWDs from the patent owner to analyze or overcome.

2. Initiate a Prior Art Search: The immediate priority should be to conduct a comprehensive prior art search targeting the key limitations of the independent claims, especially the combination of:

   • A grid of nodes with both horizontal and vertical communication channels.
   • The specific ratio where the number of channels in a row/column equals the number of nodes in that row/column.
   • The functional result of this architecture: routing data between any two nodes in a maximum of two hops.
   • The use of at least one channel to route data from a single source to two or more destination nodes (i.e., a shared bus or multicast capability).

3. Evaluate an IPR Filing: An IPR remains a potent defensive tool. A defendant has a one-year window to file an IPR petition from the date they are served with an infringement complaint, per 35 U.S.C. § 315(b). Given the recent filing date of the litigation against Intel (April 17, 2026), this statutory window is currently open. A successful IPR could invalidate the asserted claims and potentially stay the district court litigation, offering a more cost-effective and faster resolution than a full jury trial.

4. Leverage Obviousness Arguments: The "Obviousness Analysis" section provides a strong starting point for an IPR petition. A skilled PTAB litigator could build a compelling case that combining a known mesh architecture (like that in U.S. Patent No. 7,203,778) with the well-understood concept of shared-bus communication to reduce wiring complexity would have been obvious to a person of ordinary skill in the art, and that the "two-hop" characteristic is merely an inherent, predictable result of that combination.